SG11202110272SA - Prmt5 inhibitors and uses thereof - Google Patents
Prmt5 inhibitors and uses thereofInfo
- Publication number
- SG11202110272SA SG11202110272SA SG11202110272SA SG11202110272SA SG11202110272SA SG 11202110272S A SG11202110272S A SG 11202110272SA SG 11202110272S A SG11202110272S A SG 11202110272SA SG 11202110272S A SG11202110272S A SG 11202110272SA SG 11202110272S A SG11202110272S A SG 11202110272SA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- hoy
- formula
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823374P | 2019-03-25 | 2019-03-25 | |
| US201962874773P | 2019-07-16 | 2019-07-16 | |
| PCT/US2020/024654 WO2020198323A1 (en) | 2019-03-25 | 2020-03-25 | Prmt5 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110272SA true SG11202110272SA (en) | 2021-10-28 |
Family
ID=72609147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110272SA SG11202110272SA (en) | 2019-03-25 | 2020-03-25 | Prmt5 inhibitors and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12583859B2 (https=) |
| EP (1) | EP3947387B1 (https=) |
| JP (1) | JP7609798B2 (https=) |
| KR (1) | KR20220023330A (https=) |
| CN (1) | CN114127072B (https=) |
| AU (1) | AU2020245480A1 (https=) |
| BR (1) | BR112021019125A2 (https=) |
| CA (1) | CA3134779A1 (https=) |
| IL (2) | IL318073A (https=) |
| MX (1) | MX2021011524A (https=) |
| SG (1) | SG11202110272SA (https=) |
| WO (1) | WO2020198323A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| IL318073A (en) | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2022026892A1 (en) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers |
| CN117157297A (zh) * | 2021-07-20 | 2023-12-01 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
| EP4458836A4 (en) * | 2021-12-27 | 2025-05-21 | Riken Genesis Co., Ltd. | Novel artificial nucleic acid, method for producing same, and use of same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| KR102028793B1 (ko) | 2013-03-14 | 2019-10-07 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) * | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| WO2018160824A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP3939986A1 (en) * | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US11059850B2 (en) * | 2017-12-08 | 2021-07-13 | Janssen Pharmaceutica Nv | Spirobicyclic analogues |
| IL318073A (en) | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
-
2020
- 2020-03-25 IL IL318073A patent/IL318073A/en unknown
- 2020-03-25 MX MX2021011524A patent/MX2021011524A/es unknown
- 2020-03-25 KR KR1020217034437A patent/KR20220023330A/ko not_active Ceased
- 2020-03-25 SG SG11202110272SA patent/SG11202110272SA/en unknown
- 2020-03-25 EP EP20778402.6A patent/EP3947387B1/en active Active
- 2020-03-25 CA CA3134779A patent/CA3134779A1/en active Pending
- 2020-03-25 AU AU2020245480A patent/AU2020245480A1/en not_active Abandoned
- 2020-03-25 BR BR112021019125A patent/BR112021019125A2/pt not_active IP Right Cessation
- 2020-03-25 CN CN202080037608.5A patent/CN114127072B/zh active Active
- 2020-03-25 JP JP2021557342A patent/JP7609798B2/ja active Active
- 2020-03-25 WO PCT/US2020/024654 patent/WO2020198323A1/en not_active Ceased
- 2020-03-25 US US17/598,152 patent/US12583859B2/en active Active
-
2021
- 2021-09-23 IL IL286622A patent/IL286622A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3947387B1 (en) | 2024-10-23 |
| MX2021011524A (es) | 2021-12-15 |
| CN114127072A (zh) | 2022-03-01 |
| US20220194949A1 (en) | 2022-06-23 |
| BR112021019125A2 (pt) | 2021-11-30 |
| IL318073A (en) | 2025-02-01 |
| CN114127072B (zh) | 2024-10-11 |
| JP7609798B2 (ja) | 2025-01-07 |
| KR20220023330A (ko) | 2022-03-02 |
| EP3947387A4 (en) | 2022-11-30 |
| WO2020198323A1 (en) | 2020-10-01 |
| JP2022521818A (ja) | 2022-04-12 |
| AU2020245480A1 (en) | 2021-11-11 |
| US12583859B2 (en) | 2026-03-24 |
| CA3134779A1 (en) | 2020-10-01 |
| EP3947387A1 (en) | 2022-02-09 |
| IL286622A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202110272SA (en) | Prmt5 inhibitors and uses thereof | |
| AU2020279287B2 (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| JP6862495B2 (ja) | Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置 | |
| JP7502337B2 (ja) | Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 | |
| JP6893501B2 (ja) | スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン | |
| ES2679521T3 (es) | Inhibidores pirimidínicos de FGFR4 | |
| CA2997051C (en) | Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof | |
| KR102659741B1 (ko) | 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도 | |
| ES2618637T3 (es) | Compuestos, sus composiciones farmacéuticas y sus usos como inhibidores mutantes de IDH1 para el tratamiento de cánceres. | |
| US20220112204A1 (en) | Substituted dihydropyranopyrimidine compounds as kras inhibitors | |
| WO2022115439A1 (en) | Kras g12c inhibitors and uses thereof | |
| KR20160144378A (ko) | 브루톤 티로신 키나제 억제제로서 작용하는 폴리플루오로화 화합물 | |
| BR112020013237A2 (pt) | derivados de amino-metilpiperidina como iniciador quinase | |
| WO2025151765A1 (en) | Kras g12d degraders and uses thereof | |
| AU2018337138B2 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
| KR102833011B1 (ko) | 푸로[3,4-b]피롤-함유 BTK 억제제 | |
| CN115135651A (zh) | 作为prmt5抑制剂的被取代的核苷类似物 | |
| CN117916234A (zh) | 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法 | |
| KR101872264B1 (ko) | 신규한 유형의 시티딘 유도체 이량체 및 그의 용도 | |
| EP4581036A1 (en) | Egfr inhibitors and uses thereof | |
| HK40063243A (en) | Prmt5 inhibitors and uses thereof | |
| HK40063243B (en) | Prmt5 inhibitors and uses thereof | |
| CA3157015A1 (en) | Mcl1 inhibitors and uses thereof | |
| WO2021202480A1 (en) | Compounds targeting prmt5 | |
| CN121001717A (zh) | 作为cdk2抑制剂的新型大环氨基吡唑化合物 |